84-1978-80　［取扱停止］Urokinase Plasminogen Activator, CT (PLAU, plasminogen activator, urokinase, HGNC:9052, ATF, UPA, URK, u-PA , U-plasminogen activator, antagonist of uPA, plasminogen activator, urinary, urokinase plasminogen activator, urokinase-type plasminogen activator amino-terminal fragment, urokinase-type plasminogen activator precursor) (Azide free) (HRP) 200ul　U2615-15P-HRP

特徴

• PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders.
• PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin.
• The protein is found in high and low molecular mass forms.
• Each consists of two chains, A and B.
• The high molecular mass form contains a long chain A.
• Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain.
• The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis.
• Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
• Applications:Suitable for use in ELISA, Western Blot and Immunohistochemistry.
• Other applications have not been tested.
• Recommended Dilution:Immunohistochemistry: Formalin-fixed, paraffin-embedded sectionsOptimal dilutions to be determined by the researcher.
• Storage and Stability:Store product at 4°C if to be used immediately within two weeks.
• For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C.
• Aliquots are stable at -20°C for 12 months after receipt.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Note: Applications are based on unconjugated antibody.